Artificial Pancreas Device System Market

Market Synopsis:

The global Artificial Pancreas Device System Market is valued at USD 2579.4 Million in 2024 and is projected to reach a value of USD 7768 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 10.55% between 2025 and 2035. The market is being driven by factors such as rising diabetes prevalence, intense R&D activities by industry players, and rising demand for automated glycemic control systems. The blood glucose level in diabetic patients is controlled by an artificial pancreas device system, and industry participants are doing several studies to improve diabetes treatment. Furthermore, automated glycemic control technologies include insulin pumps, artificial pancreas, and insulin pens, among other devices. The flexibility, correct dosing, automatic detection of glucose level, short and rapid-acting insulin, and ease of use are all factors driving up demand for these devices.

Increasing Prevalence of Diabetes and Geriatric Population Globally

The industrys expansion will be fueled by the worlds ageing and overweight population. According to the World Health Organization, the global population of people aged 60 and more will increase from 12% in 2015 to roughly 22% in 2050. With increasing age, muscle strength and physical labor capacities deteriorate. The Artificial Pancreas Device System market will continue to grow as more medical devices are used to support and actuate body movement.

Technical Failure and Side Effects of Artificial Pancreas Device Systems

Following an unexpected insulin overdose by a diabetes patient while using the DIY APS in May 2019, the US Food and Drug Administration issued a warning to Do-it-Yourself Artificial Pancreas Systems (DIY APS). Such technological problems may have an impact on the DIY APS adoption rate, stifling market growth over the projection period.

Market Segmentation:

The Global Artificial Pancreas Device System market is segmented by Device into Threshold suspended device system, CTR System and CTT System. Based on Region, the Artificial Pancreas Device System Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Asia Pacific is Expected to Experience a Rapid Growth

During the projected period, Asia Pacific is expected to grow at the fastest rate. Because of their lifestyle, genetic alteration, urbanisation, and ageing, this region has the largest number of diabetes sufferers. Diabetes incidences are predicted to rise throughout the forecast period, boosting market growth. According to a study published by NCBI, Asian countries account for more than 60% of the worlds diabetes population, fueling the regions APDS market expansion. Furthermore, the market is likely to be boosted by industry players establishing their centres across the region.

{{Map_Image}}

Key Players:

Key players operating in the global Artificial Pancreas Device System market include Medtronic Plc., Medtrum Technologies Inc., Tandem Diabetes Care, Inc., Johnson & Johnson, Beta Bionics, Inc., Bigfoot Biomedical, Insulet Corporation, Pancreum, Inc., TypeZero Technologies, Inc., DreaMed Diabetes Ltd, and Inreda Diabetic BV.

The Artificial Pancreas Device System market is segmented as follows:

Artificial Pancreas Device System Market is tabulated as follows: